The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer

Abstract

[LANGUAGE= "English"] Objectives: Although pancreatic cancer is comparatively rare, it's the seventh cause of cancer-related mortality in the world. Surgery is the sole curative treatment option but approximately 85% of patients are diagnosed at inoperable stag?es. The standard treatment options for the advanced staged disease are 5-Fluorouracil, leucovorin, irinotecan, and oxali?platin (FOLFIRINOX) or gemcitabine-based chemotherapy. In spite of those treatments, the 5-year survival rate is less than 5%. In this study, we aimed to evaluate the prognostic value of the systemic inflammation response index (SIRI). Methods: A retrospective, single-center study consisting of 103 patients from December 2015 to December 2019, was performed. The cut-off SIRI values were determined as 1.8×109. We determine whether the SIRI was an independent prognostic parameter. Results: We observed that the median OS for metastatic pancreatic cancer patients with SIRI values <1.8×109 was bet?ter than the patients with SIRI values?1.8×109 independent of the treatment choices (17.3 months vs 11.9 months). Conclusion: SIRI seems to be an accessible, and cost-effective parameter as a strong prognostic determiner for ad?vanced pancreatic cancer. Its value is independent of the treatment choice.

Alternate abstract:

Objectives: Although pancreatic cancer is comparatively rare, it's the seventh cause of cancer-related mortality in the world. Surgery is the sole curative treatment option but approximately 85% of patients are diagnosed at inoperable stag?es. The standard treatment options for the advanced staged disease are 5-Fluorouracil, leucovorin, irinotecan, and oxali?platin (FOLFIRINOX) or gemcitabine-based chemotherapy. In spite of those treatments, the 5-year survival rate is less than 5%. In this study, we aimed to evaluate the prognostic value of the systemic inflammation response index (SIRI). Methods: A retrospective, single-center study consisting of 103 patients from December 2015 to December 2019, was performed. The cut-off SIRI values were determined as 1.8×109. We determine whether the SIRI was an independent prognostic parameter. Results: We observed that the median OS for metastatic pancreatic cancer patients with SIRI values <1.8×109 was bet?ter than the patients with SIRI values?1.8×109 independent of the treatment choices (17.3 months vs 11.9 months). Conclusion: SIRI seems to be an accessible, and cost-effective parameter as a strong prognostic determiner for ad?vanced pancreatic cancer. Its value is independent of the treatment choice.